Alnylam to Webcast Virtual RNAi Roundtable on ALN-TTR for Treatment of Transthyretin-Mediated Amyloidosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 19, 2010 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will be hosting a virtual RNAi Roundtable to discuss ALN-TTR for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR) on Thursday, July 22, 2010 at 2:00 p.m. ET.

To participate in the webcast, please register at http://bit.ly/RNAiRdTTR. A live audio webcast of the presentation will also be available on the “Investors” section of the company's website, www.alnylam.com. A replay of the RNAi Roundtable will be available on the Alnylam website within 24 hours after the event.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is leading the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world's top scientific journals including Nature, Nature Medicine, and Cell. The company is leveraging these capabilities to build a broad pipeline of RNAi therapeutics; its most advanced program is in Phase II human clinical trials for the treatment of respiratory syncytial virus (RSV) infection. In addition, the company is developing RNAi therapeutics for the treatment of a wide range of disease areas, including liver cancers, TTR-mediated amyloidosis (ATTR), hypercholesterolemia, and Huntington's disease. In addition, Alnylam formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. Alnylam and Isis are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development, and commercialization of microRNA therapeutics. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit www.alnylam.com.

Contact: Alnylam Pharmaceuticals, Inc.
Cynthia Clayton (Investors), 617-551-8207
or
Spectrum
Amanda Sellers (Media), 202-955-6222 x2597

 

 

Posted: July 2010

View comments

Hide
(web4)